Tagged with Research,

Hungary According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million each year.” Furthermore, Dr György Bodoky, founder and honorary president of the Hungarian Society of Clinical Oncology (MKOT), adds that…

Czech Republic Darina Hrdličková, chairwoman of the Association of Contract Research Organizations in the Czech Republic (ACRO-CZ), gives an overview of her new priorities and mission since taking over the position in 2018, and how dedicated she is to showcase the strengths of the Czech healthcare system and the advantages of the…

Czech Republic Vladimír Velebný, founder and CEO, celebrates his 30th anniversary heading Contipro, a mid-sized company with deep experience in R&D surrounding their star product, hyaluronic acid. Whilst breaking down the components of such a powerful and universal material, he points out that it is, in fact, an extremely simple substance; its…

Hungary Csilla Léka, general manager of Global Clinical Trials in Hungary shares her insights on the portfolio of the company, the most prevalent therapeutic areas, the developments in clinical trials over the last decade, and her outlook on the future of the company.   In comparison with Western European countries, Hungary…

China Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in China and the US, his motivation to establish Maxinovel Pharmaceuticals as a global, semi-virtual biotech, and their mission to develop a pipeline of orally-active one-pill combination of immuno-oncology…

UAE The United Arab Emirates’ Cabinet, the de facto executive branch of the federation, recently announced a set of decisions and legislation to support health research as a pillar of the country’s 50-year plan. The measures intend to support the healthcare sector, improve its quality and performance.   They include a…

Artificial Intelligence On the supply side, AI appears to herald the prospect of de-risking the drug discovery process and doing away with many of the traditional time-consuming approaches at a juncture when drug development had been becoming financially unsustainable and clinical research organisations (CROs) had been systematically failing to improve operational efficiency.…

China GemPharmatech is a fast-growing service center for production, distribution and phenotyping of gene-modified mouse models with multiple subsidiaries in China, and an upcoming one in the USA. Chairman Professor Xiang Gao discusses the company’s story, its ambitions in China and globally, its recent Series A financing round, and its close…

Hungary Dr. András Szabó, CEO of Szinapszis, a Hungarian market research and consulting agency specialized in the health industry, offers his expert insights on the key challenges and trends shaping the country’s pharma and healthcare ecosystem. Furthermore, Szabó highlights the offering Szinapszis can deliver as a partner of choice to both…

China Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually set up a multifaceted platform for MNCs and biotechs.   By having a manufacturing facility in the USA or Europe,…

China Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs of patients in China and the world.   Sinovant Sciences is set up to take an integrated approach to develop…

Hungary Laszlo Dinca, managing director of Vanessa Research – Hungary, shares his insights on the company’s rare and orphan disease portfolio; the intentions behind the acquisition of Hungaro-Gal Pharmaceutical Manufacturing [HG Biotech]; Hungary as a development market for biotechnology companies; and the future objectives of the company.   It is paramount…